Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.

Stam WB, Aversa F, Kumar RN, Jansen JP.

Value Health. 2008 Sep-Oct;11(5):830-41. doi: 10.1111/j.1524-4733.2008.00324.x. Epub 2008 May 20.

2.

A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.

Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP.

Eur J Haematol. 2007 Jun;78(6):532-9. Epub 2007 Apr 5.

3.

Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.

Naik S, Lundberg J, Kumar R, Sjolin J, Jansen JP.

Scand J Infect Dis. 2011 Jul;43(6-7):504-14. doi: 10.3109/00365548.2011.556145. Epub 2011 Feb 18.

PMID:
21332286
4.

Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.

Wingard JR, Leather HL, Wood CA, Gerth WC, Lupinacci RJ, Berger ML, Mansley EC.

Am J Health Syst Pharm. 2007 Mar 15;64(6):637-43.

PMID:
17353573
5.

Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.

Al-Badriyeh D, Liew D, Stewart K, Kong DC.

J Antimicrob Chemother. 2009 Jun;63(6):1276-85. doi: 10.1093/jac/dkp119. Epub 2009 Apr 3.

PMID:
19346292
6.

Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.

Ament AJ, Hübben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, van 't Wout J, Severens JL.

J Antimicrob Chemother. 2007 Aug;60(2):385-93. Epub 2007 Jun 7.

PMID:
17561501
7.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
8.

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE.

N Engl J Med. 2004 Sep 30;351(14):1391-402.

9.

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ; Caspofungin Pediatric Study Group.

Pediatr Infect Dis J. 2010 May;29(5):415-20. doi: 10.1097/INF.0b013e3181da2171.

PMID:
20431381
10.

Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.

Al-Badriyeh D, Liew D, Stewart K, Kong DC.

Mycoses. 2012 May;55(3):244-56. doi: 10.1111/j.1439-0507.2011.02074.x. Epub 2011 Jul 26.

PMID:
21790799
11.

Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey.

Turner SJ, Senol E, Kara A, Al-Badriyeh D, Kong DC, Dinleyici EC.

Int J Antimicrob Agents. 2013 Sep;42(3):276-80. doi: 10.1016/j.ijantimicag.2013.04.030. Epub 2013 Jul 4.

PMID:
23830892
12.
13.

Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.

Mistro S, Rosa L, Gomes B, Miranda L, Badaró R.

Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):465-73. doi: 10.1080/14737167.2016.1202766. Epub 2016 Jun 30. Review.

PMID:
27322156
14.

Caspofungin versus liposomal amphotericin B: are they really comparable?

Sekine L, Humbwavali J, Wolff FH, Barcellos NT.

Pediatr Infect Dis J. 2010 Oct;29(10):985-6; author reply 986-7. doi: 10.1097/INF.0b013e3181f2d878. No abstract available.

PMID:
20859182
15.

Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.

Kaskel P, Tuschy S, Wagner A, Bannert C, Cornely OA, Glasmacher A, Lipp HP, Ullmann AJ.

Ann Hematol. 2008 Apr;87(4):311-9. Epub 2007 Oct 11.

16.
17.

Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.

Collins CD, Stuntebeck ER, DePestel DD, Stevenson JG.

Clin Drug Investig. 2007;27(4):233-41.

PMID:
17358095
18.

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.

Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP.

Eur J Haematol. 2008 Dec;81(6):467-74. doi: 10.1111/j.1600-0609.2008.01141.x.

PMID:
18754857
19.

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J.

Clin Ther. 2015 Jun 1;37(6):1317-1328.e2. doi: 10.1016/j.clinthera.2015.03.021. Epub 2015 Apr 17.

20.

Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.

Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP.

Pharmacotherapy. 2007 Jul;27(7):970-9.

Supplemental Content

Support Center